A Phase 1 clinical study of NT0502 for the treatment of sialorrhea in patients with neurological conditions
Latest Information Update: 21 Feb 2022
At a glance
- Drugs N desethyloxybutynin (Primary)
- Indications Sialorrhoea
- Focus Adverse reactions
- Sponsors Aytu BioPharma; Neos Therapeutics
Most Recent Events
- 09 Nov 2020 According to a Neos Therapeutics media release, the company expects to initiate this trial in the first half of 2021.
- 10 Aug 2020 According to a Neos Therapeutics media release, the company expects to initiate this trial in the fourth quarter of 2020.
- 13 Mar 2020 According to a Neos Therapeutics media release, this trial is expected to begin in the second half of 2020.